Li N. Komatsu

Array ( [id] => 11936443 [patent_doc_number] => 20170240594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Therapeutic Use of Peptide Inhibitors of NADPH Oxidase; Aerosolization as a Delivery Mechanism' [patent_app_type] => utility [patent_app_number] => 15/441359 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8405 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15441359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294423 [patent_doc_number] => 10287328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same [patent_app_type] => utility [patent_app_number] => 15/441390 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 17 [patent_no_of_words] => 16283 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15441390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12016933 [patent_doc_number] => 09809626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Antibacterial agents: salinamide derivatives' [patent_app_type] => utility [patent_app_number] => 15/436446 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 12201 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647900 [patent_doc_number] => 20170143801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients' [patent_app_type] => utility [patent_app_number] => 15/197378 [patent_app_country] => US [patent_app_date] => 2017-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 22532 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15197378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182153 [patent_doc_number] => 10106578 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Melanocortin-1 receptor-specific linear peptides [patent_app_type] => utility [patent_app_number] => 15/422850 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23838 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864779 [patent_doc_number] => 20170232063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'USES OF CASEIN COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/421245 [patent_app_country] => US [patent_app_date] => 2017-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12752 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051193 [patent_doc_number] => 20170327537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS' [patent_app_type] => utility [patent_app_number] => 15/419173 [patent_app_country] => US [patent_app_date] => 2017-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 25565 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15419173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13137461 [patent_doc_number] => 10086041 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-02 [patent_title] => Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response [patent_app_type] => utility [patent_app_number] => 15/387201 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 9143 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14116973 [patent_doc_number] => 10245327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-02 [patent_title] => Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate [patent_app_type] => utility [patent_app_number] => 15/374805 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 86 [patent_no_of_words] => 12428 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15374805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649156 [patent_doc_number] => 20170145057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'ANTIMICROBIAL PEPTIDES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/371683 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 14225 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15371683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750451 [patent_doc_number] => 20180141984 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => ANTIMICROBIAL PEPTIDE ANALOGUES DERIVED FROM ABALONE (HALIOTIS DISCUS) AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 15/364398 [patent_app_country] => US [patent_app_date] => 2016-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15364398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514245 [patent_doc_number] => 20170081319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein' [patent_app_type] => utility [patent_app_number] => 15/364841 [patent_app_country] => US [patent_app_date] => 2016-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 11781 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15364841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12428298 [patent_doc_number] => 09975940 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-22 [patent_title] => Long-acting single-chain insulin analogues [patent_app_type] => utility [patent_app_number] => 15/358977 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6670 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15358977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11497826 [patent_doc_number] => 20170072011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'METHODS OF TREATMENT USING HEMOPEXIN COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/358368 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9477 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15358368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051523 [patent_doc_number] => 10047142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Factor VIII variants having a decreased cellular uptake [patent_app_type] => utility [patent_app_number] => 15/355475 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 20149 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13926177 [patent_doc_number] => 20190046604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => LABYRINTHOPEPTINS AS ANTI-VIRAL AGENTS [patent_app_type] => utility [patent_app_number] => 15/776522 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13853985 [patent_doc_number] => 10188699 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => CAPCNA peptide therapeutics for cancer [patent_app_type] => utility [patent_app_number] => 15/353881 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12295 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554243 [patent_doc_number] => 20170100489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'POLYETHYLENE GLYCOL-MODIFIED INTEGRIN BLOCKER HM-3 AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/332539 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13344 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15332539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555193 [patent_doc_number] => 20170101439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'GAMMA-AA-PEPTIDE STAT3/DNA INHIBITORS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/332402 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 6438 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15332402 [rel_patent_id] =>[rel_patent_doc_number] =>)